

## Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2015

(Pursuant to Article L.233-8 II of the French Commercial Code  
and articles 221-1 and 223-16 of the General Regulations of the *Autorité des Marchés Financiers*)

Charenton-le-Pont, France (February 10, 2015 - 6:00 p.m.) – As of January 31, 2015, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

January 31, 2015

Shares outstanding	215,979,614
Exercisable voting rights	228,575,186
Total voting rights, based on all outstanding shares, including shares stripped of their voting rights*	232,535,107

(\*) Shares held by the Company.

### About Essilor

The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to correct and protect eyesight. Its corporate mission is to improve vision to improve life. To support this mission, the Company allocates more than €150 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Essilor's flagship brands are Varilux<sup>®</sup>, Crizal<sup>®</sup>, Transitions<sup>®</sup>, Definity<sup>®</sup>, Xperio<sup>®</sup>, Optifog<sup>™</sup>, Foster Grant<sup>®</sup>, Bolon<sup>®</sup> and Costa<sup>®</sup>. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of over €5 billion in 2013 and employs more than 55,000 people. It distributes its products in some 100 countries with 28 plants, more than 450 prescription laboratories and edging facilities, as well as several research and development centers around the world.

For more information, please visit [www.essilor.com](http://www.essilor.com).

The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

-----  
**Investor Relations and Financial Communications**

Phone: +33 (0)1 49 77 42 16

Regulatory Information